Q2 2026 Agilent Technologies Inc Earnings Call Transcript
Key Points
- Agilent Technologies Inc (A) reported stronger-than-expected revenue growth of 6.3% on a core basis, exceeding the high end of their guidance.
- The company achieved significant margin expansion with an operating margin of 26.4%, representing a year-over-year improvement of 130 basis points.
- Earnings per share grew by 14% year-over-year, surpassing the top end of their guidance.
- Agilent's Ignite operating system is delivering structural benefits, including strategic pricing and productivity initiatives, contributing to top-line momentum and margin improvement.
- The company is experiencing strong growth across key end markets, including Pharma, Chemical and Advanced Materials, and Diagnostics and Clinical, with notable performance in forensics and semiconductor demand.
- The Food segment experienced a decline of 3% due to delays in government funding in China and India, leading to a reduction in guidance for this segment.
- China's revenue declined by 9% in the quarter, slightly more than expected, due to funding delays and tightened government spending.
- The Academia and Government segment saw a decline of 5%, with ongoing uncertainty around multiyear grants and funding concentration.
- Inflationary pressures and geopolitical challenges, such as the Middle East conflict, are impacting costs and could pose risks to future performance.
- The company faces tougher year-over-year comparisons in the second half of the fiscal year, which could challenge maintaining the current growth momentum.
Ladies and gentlemen, thank you for joining us, and welcome to the Q2 2026 Agilent Technologies Inc. earnings conference call. (Operator Instructions)
I will now hand the conference over to Tejas Savant, Vice President of Investor Relations. You may begin.
Thank you, Karina, and welcome, everyone, to Agilent's conference call for the second quarter of fiscal year 2026. With me on the line are CEO, Padraig McDonnell; and CFO, Adam Elinoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelica Reimann, President of the Agilent CrossLab Group; and Mike Zhang, President of the Applied Markets Group.
This presentation is being webcast live. The press release for our second-quarter financial results, investor presentation and information to supplement today's discussion, along with a recording of this webcast, are available on our website at investor.agilent.com.
Today's comments will refer to non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
